Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Late Immunosuppression in High-Risk Idiopathic Membranous Nephropathy
NCT00135954Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 1997
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, prednisone and methylprednisolone in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Renal function (serum creatinine), Remission of proteinuria and 2 more. Started Jul 1997; status: completed.
02
Drugs
cyclophosphamideprednisonemethylprednisolone
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT00135954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135954.